First liquid biopsy for NSCLC to receive FDA approval

The development of new targeted therapies for non-small cell lung cancer (NSCLC) in recent years has changed the standard of care for the later stages of NSCLC in specific population groups.

ESMO-releases-the-first-guideline-on-NGS-testing- in-cancers

ESMO releases the first guideline on NGS testing in cancers

Precision therapies were first approved for cancer in 1998, when trastuzumab was approved for HER2+ breast cancer, opening the door for other targeted therapies such as imatinib for Philadelphia chromosome-positive chronic myelogenous leukaemia.